(Health Korea News / Changyong Lee) JW Pharmaceutical announced on the 6th that it recorded sales of 176.6 billion won on a separate basis in the third quarter through a disclosure of provisional business results. This is a 3.5% decrease compared to the same quarter last year (KRW 183 billion).
Operating profit during the same period was 26.3 billion won, a 1.6% decrease compared to the same period last year (26.8 billion won). On the other hand, net profit for the period was 19.7 billion won, turning into a surplus compared to the same quarter last year.
As a result, JW Pharmaceutical’s cumulative sales for the first to third quarters were KRW 525.4 billion and cumulative operating profit was KRW 65.6 billion, down 2.3% and 7.6%, respectively, compared to the same period last year. Cumulative net profit attracted attention by recording 48.8 billion won, a 205.9% surge compared to the same period last year (15.9 billion won).
(Joongwae Pharmaceutical’s provisional operating results for the third quarter of 2024 on a separate basis)
|
division(unit: million won%) |
Current performance |
previous year performance |
Rate of change compared to the previous quarter(%) |
Performance for the same period last year |
Rate of change compared to the same period last year(%) |
|
|
(24year 3branch) |
(24year 2branch) |
(23year 3branch) |
||||
|
take |
Current performance |
176,564 |
170,659 |
3.5% |
182,921 |
-3.5 |
|
Cumulative performance |
525,442 |
348,878 |
– |
537,772 |
-2.3 |
|
|
operating profit |
Current performance |
26,340 |
12,502 |
110.7 |
26,756 |
-1.6 |
|
Cumulative performance |
65,554 |
39,215 |
– |
70,971 |
-7.6 |
|
|
net profit |
Current performance |
19,691 |
9,186 |
114.3 |
-17,780 |
Turn to surplus |
|
Cumulative performance |
48,770 |
29,079 |
– |
15,945 |
205.9 |
|
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
